The RAS/MAPK (mitogen-activated protein kinase) signalling pathway is frequently deregulated in non-small-cell lung cancer, often through KRAS activating mutations 1-3 . A single endogenous mutant Kras allele is sufficient to promote lung tumour formation in mice but malignant progression requires additional genetic alterations 4-7 . We recently showed that advanced lung tumours from Kras G12D/+ ;p53-null mice frequently exhibit Kras G12D allelic enrichment (Kras G12D /Kras wild-type > 1) (ref. 7), implying that mutant Kras copy gains are positively selected during progression. Here we show, through a comprehensive analysis of mutant Kras homozygous and heterozygous mouse embryonic fibroblasts and lung cancer cells, that these genotypes are phenotypically distinct. In particular, Kras G12D/G12D cells exhibit a glycolytic switch coupled to increased channelling of glucose-derived metabolites into the tricarboxylic acid cycle and glutathione biosynthesis, resulting in enhanced glutathione-mediated detoxification. This metabolic rewiring is recapitulated in mutant KRAS homozygous nonsmall-cell lung cancer cells and in vivo, in spontaneous advanced murine lung tumours (which display a high frequency of Kras G12D copy gain), but not in the corresponding early tumours (Kras G12D heterozygous). Finally, we demonstrate that mutant Kras copy gain creates unique metabolic dependences that can be exploited to selectively target these aggressive mutant Kras tumours. Our data demonstrate that mutant Kras lung tumours are not a single disease but rather a heterogeneous group comprising two classes of tumours with distinct metabolic profiles, prognosis and therapeutic susceptibility, which can be discriminated on the basis of their relative mutant allelic content. We also provide the first, to our knowledge, in vivo evidence of metabolic rewiring during lung cancer malignant progression.
To identify both immediate and proliferation-independent Kras G12D copy-gain-dependent effects, subsequent analyses were restricted to early passages. While KRAS amplifications are typically associated with increased expression 2,10 , Kras G12D/WT and Kras G12D/G12D Ras protein levels were comparable and only slightly increased relative to Kras WT/WT MEFs. Nevertheless, Kras G12D/G12D MEFs exhibited a ~2-fold increase in activated Ras relative to Kras G12D/WT cells (Fig. 1c ), indicating that mutant copy gain may have functional implications. In agreement, microarray analysis identified 1,666 genes differentially regulated (>1.3-fold) between Kras G12D/G12D and Kras G12D/WT MEFs, with glycolysis being the most significantly altered pathway ( Fig. 1d and Extended Data Fig. 1b ).
Mutant Kras activity enhances glucose uptake and rewires glucose metabolism into the hexosamine biosynthesis and pentose phosphate pathways in pancreatic ductal adenocarcinoma 13 . However, its metabolic impact on other cancer types and, more importantly, that of Kras mut copy gain is unclear. Kras G12D/WT and Kras WT/WT MEFs showed similar glycolytic gene expression profiles with the exception of Slc2a1 (Glut1) and Slc2a3 (Glut3, data not shown). In contrast, in Kras G12D/G12D MEFs, glycolytic gene expression was significantly upregulated and mirrored by increased glucose uptake, lactate secretion and glycolytic capacity (Fig. 1e , f and Extended Data Fig. 1c, d) . Thus, we show that Kras G12D copy gain induces a glycolytic switch while a Kras mutation per se is not sufficient to upregulate glycolysis. Notably, analysis of murine lung tumour cell lines with distinct Kras G12D/WT allelic content revealed a direct correlation between increased Kras G12D copy number (Kras G12D /total Kras) and enhanced GTPase activity as well as glycolysis (extracellular acidification rate, ECAR), consistent with a 'Kras mut -dosage' effect. Glycolytic gene expression, glucose uptake and lactate secretion were also significantly enhanced in Kras G12D/G12D relative to heterozygous lung tumour cells ( Fig. 1g and Extended Data Fig. 1e-g) . Importantly, KRAS mut homozygosity is highly prevalent (48.6%) within mutant KRAS NSCLC cell lines (COSMIC), emphasizing its relevance and enabling the validation of our findings in a clinically relevant NSCLC model. Reassuringly, the distinct glycolytic phenotypes of KRAS mut heterozygous and homozygous cells were confirmed in NSCLC cells ( Fig. 1h and Extended Data Table 1 ), demonstrating that glycolysis upregulation is a Kras mut copy-gain-associated gain-of-function.
Enhanced glycolysis is a well-recognized cancer phenotype typically associated with increased growth demands, and/or compensatory adaptation to mitochondrial defects 14, 15 . Yet, early passage Kras G12D/G12D MEFs displayed a glycolytic switch relative to Kras G12D/WT cells despite exhibiting comparable proliferative rates, cell volume, diameter, protein and RNA content (Fig. 1a, b and Extended Data Fig. 2a-d ). Furthermore, mitochondrial morphology and function were similar across genotypes (Extended Data Fig. 2e-h) , despite a Kras G12D -associated decrease in membrane potential, as reported under overexpression conditions 15, 16 . We then hypothesized that this glycolytic switch reflected alternative glucose utilization by Kras G12D/G12D cells. Liquid chromatography-mass spectrometry (LC-MS)-based metabolomics analysis confirmed the Figure 1 | Mutant Kras copy gain upregulates glycolysis in MEFs and lung tumour cells. a, Proliferative rate of Kras WT/WT (WT/WT), Kras G12D/WT (G12D/WT) and Kras G12D/G12D (G12D/G12D);p53 Fx/Fx MEFs. p53 is also known as Trp53 in mice (TP53 in humans). b, Fluorescence-activated cell sorting (FACS) analysis denoting BrdU+ MEFs. c, MEF Ras levels (immunoblotting) and activation (Raf-GST pull-down, normalized to WT/WT). d, Heatmap illustrating differential gene expression between G12D/WT and G12D/G12D MEFs (n = 3 per genotype, microarray); top canonical pathways altered shown (Ingenuity Pathway Analysis, IPA). e, Glycolytic gene expression (MEF microarray-based heatmap). Genes significantly upregulated in G12D/G12D cells highlighted (bold red, t-test). f, MEF glucose consumption and lactate secretion. g, Left: Kras G12D /Kras Total allelic frequency (pyrosequencing) versus Ras activation or glycolysis (ECAR) in Kras G12D/WT ;p53-deficient murine lung tumour cells (n = 6) (Pearson's correlation). Right: glucose consumption and lactate secretion in G12D/WT and G12D/G12D cell line pair (t-test). h, Ras activation (normalized to H358), glucose consumption and lactate secretion in KRAS mut heterozygous (HET: H23, H358) or homozygous (HOM: H460, SW1573) NSCLC cell lines. c, f, h, One-way analysis of variance (ANOVA). a-c, Representative data of three independent MEFs per genotype; d-f, n = 3 per genotype. g, h, Histograms: representative data (n = 3 independent experiments). All graphs depict triplicate mean ± s.d. (error bars). ***P < 0.001; **P < 0.01; *P < 0.05. Pathway impact (%)
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The metabolic heterogeneity of Kras mut cells can potentially limit the efficacy of generalized targeting approaches 22 , prompting us to explore potential Kras mut copy number-dependent susceptibilities. Unlike heterozygotes, Kras G12D/G12D MEFs were very sensitive to low glucose levels and the glucose analogue 2-deoxy-d-glucose (2DG), which induced a notable apoptotic response ( Fig. 3g, h ). In turn, Kras G12D/WT MEFs showed higher sensitivity to low glutamine. Confirming a reliance on glucose for efficient ROS management, Kras G12D/G12D cells (but not Kras WT/WT or Kras G12D/WT ) showed increased ROS levels upon 2DG treatment, while N-acetyl-l-cysteine (NAC, GSH precursor) partly rescued their 2DG-induced apoptosis (Extended Data Fig. 6b , c). Moreover, combined 2DG and l-buthionine-S,R-sulfoximine (BSO, GSH biosynthesis inhibitor 23 ) treatment induced drastic, Kras G12D/G12Dspecific apoptosis and a reduction in GSH/GSSG ratio ( Fig. 3h and Extended Data Fig. 6d ). Likewise, murine and human Kras mut homozygous lung cancer cells exhibited increased GSH levels, GSH/GSSG ratio and enhanced sensitivity to low glucose, 2DG and 2DG/BSO, relative to heterozygotes (Fig. 3i , j and Extended Data Fig. 6e-g) , revealing a mutant Kras copy-gain-specific susceptibility to glucose and glutathione depletion in lung cancer cells.
Finally, we defined the metabolic impact of Kras G12D copy gain in vivo using the spontaneous Kras G12D/+ ;p53 −/− lung tumours where these gains were originally reported 7 . These tumours progress over time from low-to high-grade, with Kras G12D gains being associated with the latter, prompting us to compare glucose flux in early (mostly low-grade) and late (typically advanced) tumours. Control or tumour-bearing mice were infused with 13 C-glucose and normal lung or individual tumours isolated for LC-MS analysis and biopsied for Kras locus assessment. Early tumours and control lung showed similar Kras G12D allelic content (means 46.7% and 46.2% respectively; Fig. 4a ), demonstrating that early lesions are predominantly 
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utilization and detoxi cation NS LETTER RESEARCH heterozygous. In contrast, late tumours showed increased Kras G12D allelic prevalence (mean > 50%), confirming mutant enrichment in advanced disease 7 . Importantly, and consistent with our in vitro data, late tumours exhibited an increase in glucose-derived TCA cycle metabolites, as well as serine, glycine and GSH ( Fig. 4b and Extended Data Fig. 7) . Notably, by showing that early and late tumours have distinct metabolic profiles, we provide, to our knowledge, the first evidence of in vivo metabolic reprogramming during lung cancer malignant progression. Kras G12D copy gain also drove increased malignancy in MEFs and lung cancer cells ( Fig. 4c-e ). Accordingly, Kras G12D/G12D MEFs showed a highly penetrant colonization phenotype inducing lung tumours in eight out of eight recipient mice following intravenous transplantation. In contrast, none of the Kras WT/WT (n = 5, data not shown) and only one out of eight Kras G12D/WT recipients developed a lung lesion. Similarly, Kras G12D/G12D lung cancer cells exhibited a significantly increased metastatic potential relative to heterozygous cells, establishing a direct link between Kras mut gains and lung cancer malignancy.
Lastly, we defined the therapeutic impact of glucose metabolism rewiring in vivo by treating early and late lung tumours with 2DG + BSO. Similarly to MEFs and lung cancer cells, late tumours (where Kras G12D allele prevalence is increased (Fig. 4a) ) were significantly more sensitive than early tumours to 2DG + BSO treatment ( Fig. 4f ). Thus, despite the presence of a Kras G12D allele (and p53 inactivation) in both groups and their comparable proliferation ( Fig. 4f , CTRL), low and high-grade lung tumours have distinct and mutant Kras copy number-dependent therapeutic susceptibilities.
Kras allelic imbalance 7 and mutant Kras upregulation 9 were shown to select for p53 inactivation and correlate with tumour progression, but the oncogenic effects of enhanced mutant Kras signalling remained unclear. Here we show that even in the absence of p53, Kras G12D/WT and Kras G12D/G12D cells are phenotypically distinct, with mutant Kras copy gain driving gain-of-functions that include upregulation and reprogramming of glucose metabolism, enhanced ROS management and increased metastatic potential. It is possible that loss of the Kras WT allele contributes to the phenotypes observed in Kras G12D/G12D cells 24, 25 . However, since the majority of advanced murine lung tumours retain the wild-type allele (Fig. 4a ), we argue that mutant Kras gains are the more likely target of positive selection during lung cancer progression. In agreement, KRAS WT -loss is uncommon whereas mutant and wildtype KRAS gains are frequent features of mutant KRAS human lung adenocarcinoma 2,10,26 .
Importantly and consistent with our findings, TCGA copy number variation and RNaseq data analysis of 65 mutant KRAS lung adenocarcinomas 1 revealed that, despite likely allelic gain heterogeneity 10 , combined KRAS mutation and copy gain correlate with glycolysis and glutathione metabolism pathway upregulation (KRAS mut&CG , Fig. 4g and Extended Data Table 2 ). These data confirm that mutant KRAS lung tumours are not a single metabolic entity and that, similarly to murine tumours, they may comprise (at least) two disease subgroups with distinct genetic and metabolic signatures and unique therapeutic susceptibilities. We argue that this heterogeneity may have contributed to the poor treatment responses of KRAS mutant tumours and hence that combined quantitative and qualitative KRAS locus assessment may have both prognostic and therapeutic utility.
Gene expression profiling, IPA and qPCR validation. Microarray analysis was performed on three independent MEFs per genotype using Illumina MouseWG-6 version 2.0 Expression BeadChip (Department of Pathology, Cambridge University). Normalized log 2 values were determined and average log fold change (logFC) calculated for each comparison. Pathway analysis of genes differentially expressed (>1.3-fold) between genotypes was performed using IPA software (http://www.ingenuity.com) and statistical significance (P < 0.05) of canonical pathways determined by Benjamini-Hochberg multiple testing correction. Relative gene expression was depicted by heatmaps generated using GENE-E software and statistical significance (P < 0.05) determined by t-test. Gene expression changes were validated by qPCR using ROCHE Universal Probe Library System or Life Technologies probes and all data normalized to 18S expression. Immunohistochemistry. H&E and Ki67 (Bethyl Laboratories, IHC-00375) immunohistochemistry was performed on formalin-fixed, 5 μm paraffin-embedded tissue sections. For transplantation studies, the total number of tumours in a single representative H&E section per animal (minimum of four lung lobes per section) is shown. For endogenous tumours, the percentage of proliferating cells was determined as Ki67 + /DAPI + nuclei per tumour from a single representative section per animal (minimum of four lung lobes per section)). All cells or a minimum of 4,000 (and >50% coverage) DAPI + nuclei per tumour were counted from an average of 5.25 tumours per mouse. Extracellular flux profiling. Oxygen consumption rate and ECAR levels were determined using a Seahorse XF e 24 analyser. Twenty thousand MEFs or 4 × 10 4 tumour cells were plated in Seahorse XF e 24 assay plates. Immediately before analysis, media was replaced by bicarbonate-free DMEM (Sigma) supplemented with 143 mM NaCl, 2% FBS and, where appropriate, 25 mM Glucose, 4 mM l-glutamine, pH 7.4 and cells incubated at 37 °C for 30 min in a CO 2 -free incubator. Each cycle of measurement involved 3 min mixing, 3 min waiting and 3 min measuring. After baseline measurements, testing agent prepared in assay medium was injected and followed by subsequent measuring cycles. Glycolysis stress test: measurement 1-3, basal (no glucose); 4-6, glucose (10 mM); 7-9, complex V inhibitor oligomycin (1 μM); and 10-12, 2-deoxyglucose (2DG, 100 mM). Mitochondrial stress test: measurement 1-3, normal (basal + 25 mM glucose); 4-6, oligomycin (1 μM); 7-9, carbonyl cyanide m-chlorophenylhydrazone (CCCP, 500 nM); and 10-12, rotenone (1 μM). Protein content (BCA assay, Thermo Fisher) at endpoint or cell number was used for data normalization. Metabolomics analysis. In vitro sample preparation. Five hundred thousand MEFs or tumour cells were supplemented with media containing uniformly labelled 13 C-glucose (25 mM) or glutamine (4 mM) for 4 h before sampling. Metabolites were extracted from media (extracellular) and cell pellet (intracellular) in 50% MeOH: 30% AcetoNitrile: 20% H 2 O + 100 ng ml −1 HEPES buffer (1 ml per 10 6 cells). Samples were incubated at 4 °C for 15 min at 700 r.p.m., before centrifugation at 13,000 r.p.m. (15,700g) . Supernatant was transferred to vials for mass spectrometry analysis.
In vivo sample preparation. Kras G12D/WT ;p53 Fx/Fx mice were anaesthetized (isofluorane inhalation) and administered a bolus of 0.4 mg g −1 body weight 13 C-glucose by tail vein intravenous injection before continuous infusion of 0.012 mg g −1 min −1 at 150 μl h −1 for 3 h. Normal lungs and independent lung tumours were collected and snap frozen. Samples were transferred to Precellys24 tubes, metabolite extraction buffer (as above) was added (250 μl per 10 mg), samples homogenized, centrifuged at 13,000 r.p.m. (15,700 g) and supernatant used for mass spectrometry analysis. Before analysis, tissues were biopsied for Kras allelic assessment (pyrosequencing).
LC-MS metabolomics. Sequant Zic-pHilic (150 mm × 2.1 mm, internal diameter 5 μm) column and guard column (20 mm × 2.1 mm, internal diameter 5 μm) from HiChrom were used for LC separation. Mobile phase A: 20 mM ammonium carbonate plus 0.1% ammonia hydroxide in water. Mobile phase B: acetonitrile. Flow rate was maintained at 180 μl min −1 and the gradient was as follows: 0-1 min 70% of B; 16 min 38% of B; 16.5 min 70% of B; 25 min 70% of B. A mass spectrometer (Thermo QExactive Orbitrap) was operated in full MS and polarity switching mode. Samples were randomized to avoid machine drifts and run in triplicate. Spectra were analysed using XCalibur Qual Browser and XCalibur Quan Browser softwares (Thermo Scientific) by referencing to an internal library of compounds. Relative metabolite abundance was calculated as the percentage of the indicated isotopologue to the total pool size of that metabolite, and depicted graphically or as a heatmap using GENE-E software. Samples were run and processed blindly. Glucose consumption and lactate measurements. For glucose consumption analysis, 1 × 10 5 MEF or tumour cells were incubated for 1 h with fluorescent 6-NBDG (N-23106, Life Technologies) and analysed by FACS (percentage of NBDG-positive cells). Lactate production was assessed 48 h after plating using Lactate Reagent (Trinity Biotech, Ireland), according to the manufacturer's instructions. Total lactate was normalized to cell number.
METHODS

Mice, adenoviral infection and treatments. Animals were maintained under SPF conditions and in compliance with UK Home Office regulations.
Kras LSL-G12D (ref. 6) mice were crossbred to p53 Fx (ref. 12 ) to obtain mixed background (C57Bl/6/129/Sv) Kras LSL-G12D/+ ;p53 Fx/Fx (for spontaneous tumours and MEF generation) or Kras +/+ ,p53 +/+ (transplantation recipients) mice. Endogenous lung tumours were generated through intranasal administration of 8-to 10-weekold Kras LSL-G12D/+ ;p53 Fx/Fx mice (termed Kras G12D/WT ;p53 null ) with Cre-expressing adenovirus (5 × 10 7 plaque-forming units per mouse, University of Iowa Vector Core), as previously described 7 . For therapeutic studies, tumour-bearing mice were treated 12 (early group) or 16 weeks (late group) after Cre administration with a combination of 1,000 mg kg −1 2DG and 10 mmol kg −1 BSO or vehicle (saline) once a day for 2 days (intraperitoneal). Lungs were collected 24 h after the last treatment and formalin fixed (of note: 2DG + BSO treatment was sometimes associated with a temporary decrease in motility in both control and tumour-bearing mice).
For transplantation studies, 8-to 12-week-old syngeneic wild-type mice were sublethally irradiated (4 Gy, caesium source) 6 h before tail vein injection with 1 × 10 5 cells in 100 μl PBS. Baseline luminescence values were collected 24 h after transplantation and tumour growth monitored weekly by bioluminescence imaging after intraperitoneal injection with d-luciferin (150 mg/kg body weight) using an IVIS Spectrum Xenogen machine (Caliper Life Sciences). Relative luciferase activity corresponds to change from baseline at indicated time point, normalized to blank control (luciferase-negative animal). For tumour load analysis, lungs were collected 3 weeks after transplantation, whereas tumour survival represents the onset of moderate signs of disease. Two independent MEFs per genotype were used in transplantation studies (four recipients per MEF line). Lung cancer cell lines (L1211 and L1212) were each transplanted onto five (tumour load study) or nine recipient mice (survival). All studies involved animals of both sexes and no animals were excluded from the analysis. Cohort sizes were calculated on the basis of published data 7 , and pilot studies and animals were randomized on the basis of gender and age. Tumour analysis was performed blindly. No tumour exceeded the maximum size approved by the animal welfare committee/regulations. Generation and culture of MEFs and tumour cell lines. For MEF generation, Kras LSL-G12D/+ ;p53 Fx/Fx animals were interbred and embryos collected at embryonic day (E)12.5, to overcome Kras LSL-G12D/G12D embryonic lethality 27 , and Cremediated recombination performed immediately after MEF generation. In short, cells were cultured in DMEM supplemented with 10% FBS, 2 mM l-glutamine for one passage and then infected with adenovirus-Cre (5 × 10 7 plaque-forming units per 1 × 10 6 cells). Cre-mediated recombination was confirmed by PCR. MEF data were typically obtained using three independent MEFs per genotype and a minimum of two independent MEFs per genotype was used in all cases. All (short-term) assays were performed in low-passage MEFs (P1-P4 post-Cre). For assessment of proliferative capacity, MEFs were cultured under standard 3T3 protocol. Briefly, at every passage 3 × 10 5 cells were plated in triplicate on 6 cm plates and counted 3 days later. Cumulative cell number was calculated as log(N f /N i )/log 2 , where N i and N f correspond to number of cells plated and final counts/passage, respectively. Murine lung tumour cell lines were generated from independent, spontaneous 'late' lung tumours from three Kras LSL-G12D/+ ;p53 R270H/ER (refs 6, 28) mice. Tumour cells were dissociated by collagenase/dispase (Roche) treatment and cultured in DMEM/ F12 media supplemented with 10% FBS, 2 mM l-glutamine. Human NSCLC cell lines were recently purchased from ATCC (authenticated) and cultured in RPMI media supplemented with 10% FBS, 2 mM l-glutamine.
AnnexinV/PI FACS analysis was performed as described 29 . For BrdU/PI FACS cells were labelled with 10 mM BrdU (Sigma) for 2 h. After harvest, cells were fixed and stained with FITC-conjugated Anti-BrdU monoclonal antibody (Becton Dickinson), according to the manufacturer's protocol and resuspended in PBS containing 20 μg ml −1 of propidium iodide (PI). FACS was performed using a LSRII (BD) flow cytometer and analysed with FlowJo software (Treestar). Cell viability following nutrient deprivation and H 2 O 2 administration was determined by Trypan Blue exclusion (0.4%, Gibco) or Crystal Violet (0.2%, Sigma), respectively. For in vivo luciferase imaging, MEFs and tumour cells were transduced with an MSCV-luciferase-hygromycin retrovirus and selected (350 μg ml −1 hygromycin B) before intravenous transplantation. All cells used in this study tested negative for mycoplasma contamination. In vitro assays were performed in triplicate and run at least three independent times. Ras and PDH expression and activity. Ras activation was determined by Raf-GST pull-down-based ELISA using 100 μg protein/sample (whole-cell lysates) (Merck Millipore, Ras activation ELISA kit, . PDH activity was determined with a PDH enzyme activity assay kit (ab109902, Abcam), according to the manufacturer's instructions. Immunoblotting (40 μg protein per sample) was performed with anti-Ras (Cell Signalling, 3339), anti-phospho-Pdhe1a (Ser 293; AP1062; Calbiochem), total Pdhe1a (9H9AF5; 459400; Life Technologies) or anti-β-tubulin (Cell Signalling 2146, loading control) antibodies.
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TCGA data set analysis. Lung adenocarcinoma patient TCGA data 1 (no restrictions) was downloaded from c-Bioportal and KRAS mutation and copy number assessed. Tumours with a KRAS mutation and KRAS GISTIC score of 0+ were taken forward for analysis (n = 65). Samples were divided into two cohorts based on GISTIC classification: KRAS mut (mutation only, GISTIC = 0, n = 36) or KRAS mut&CG (mutation and copy gain, GISTIC = 1&2, n = 29). KRAS copy number was calculated (2 CNV × 2) from SNP6 data. Pathway analysis was performed on the basis of RNaseq 1 metabolic gene expression data (1,430 genes) using IPA software, as described above. Reagents. Metabolic probes: 6-NBDG (30 μM), Mitotracker Green (50 nM), TMRM (50 nM), NAO (200 nM) and Cell Rox deep red (5 μM) were obtained from Life Technologies. Cellular ROS was determined using CellRox deep red probe (Life Technologies, C10422) and FACS analysis. GSH/GSSG and NADPH/ NADP levels and ratios were calculated according to the manufacturer's instructions (Promega, V6611 and G9081, respectively). Normal and low GLC and GLN (Sigma) correspond to 25 mM and 5 mM, and 4 mM and 0.5 mM, respectively. Cells were treated with the following agents, either alone or in combination as indicated: 100 μM H 2 O 2 , 10 mM 2DG and 2 mM (tumour cells) or 5 mM BSO (MEFs). Total protein content was assessed using Sulforhodamine B (Sigma, 0.057% w/v), and total RNA content extracted with TRIzol (Life Technologies). NAC (4 mM, Sigma) was added to cells daily. Pyrosequencing analysis. Genomic DNA (from MEFs, tumour cells and tumours) was isolated and the Kras WT/mutant allelic ratio determined by pyrosequencing (PyromarkQ24, Qiagen) according to the manufacturer's instructions. Pyrograms were analysed (PyroMarkQ24 software) and WT and mutant Kras allelic frequency determined on the basis of standards (WT:mutant ratios 2:0, 1:1, 0:2) and shown as the percentage of total Kras content. Slc2a1: forward 5′-GGATCCCAGCAGCAAGAAG-3′, reverse 5′-CCAGTGTTA TAGCCGAACTGC-3′; Probe 76; Pfkl: forward 5′-GGGTCATGTACA GCGAGGA-3′, reverse 5′-GGCCTCCATACCCATCTTG-3′; Probe 41; Eno1: forward 5′-GAGGACACTTTCATCGCAGAC-3′, reverse 5′-CCAGCTCTTC CTCAATTCTGA-3′; Probe 77; Nrf2: Mm00477784_m1, Ldha: Mm01612132_m1 (Life Technologies), 18S: 4352930E (Thermo Fisher). Pyrosequencing: (Qiagen Q24 pyrosequencing assay) mKras G12D forward 5′-GTAAGGCCTGCTGAAA ATGACTGA-3′; mKras G12D reverse 5′-[Btn]TATCGTCAAGGCGCTCTTGC-3′, mKras G12D sequencing primer 5′-TGAAAATGACTGAGTATAAA-3′. Statistical analysis. Data were visualized and statistical analyses performed using Prism 5.0 software (Graph Pad) or R statistical package. P < 0.05 was considered statistically significant. In all cases, experimental groups showed comparable variance. P values for unpaired comparisons between two groups with comparable variance were calculated by two-tailed Student's t-test. Oneway ANOVA (all groups against wild-type (WT) group) was used for analysis between three or more groups with comparable variance, followed by Bonferroni post-test for individual comparisons. Ordinary two-way ANOVA (treatment groups against individual genotype control group with comparable variance) was used for analysis that involved two variables, followed by Bonferroni post-test for individual comparisons. Kaplan-Meier comparison was used for analysis of survival cohorts. Pearson's correlation analysis was used to compare relationships between variables in groups with similar distribution. TCGA gene expression data were analysed using a negative binomial generalized linear model (DESeq2). *P < 0.05; **P < 0.01; ***P < 0.001. Error bars, mean ± s.d. or s.e.m., as indicated. 
